607 related articles for article (PubMed ID: 33350295)
1. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
[TBL] [Abstract][Full Text] [Related]
2. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model.
Chrom P; Stec R; Bodnar L; Szczylik C
Cancer Res Treat; 2018 Jan; 50(1):103-110. PubMed ID: 28253564
[TBL] [Abstract][Full Text] [Related]
3. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.
Hu H; Yao X; Xie X; Wu X; Zheng C; Xia W; Ma S
World J Urol; 2017 Feb; 35(2):261-270. PubMed ID: 27255479
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
7. The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma.
Yuk HD; Kang M; Hwang EC; Park JY; Jeong CW; Song C; Seo SI; Byun SS; Kwak C; Hong SH; Chung J; Lee H;
Investig Clin Urol; 2020 Sep; 61(5):475-481. PubMed ID: 32734724
[TBL] [Abstract][Full Text] [Related]
8. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
9. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
11. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.
Albisinni S; Pretot D; Al Hajj Obeid W; Aoun F; Quackels T; Peltier A; Roumeguère T
Prog Urol; 2019; 29(8-9):423-431. PubMed ID: 31196826
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
Jia W; Yuan L; Ni H; Xu B; Zhao P
Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
17. Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.
Li T; Li H; Xie S; Tan Y; Xie ZP; Li WY; Ai F
Pathol Oncol Res; 2020 Apr; 26(2):1319-1324. PubMed ID: 31388933
[TBL] [Abstract][Full Text] [Related]
18. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
20. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]